Sociedad Americana de Hirudoterapia

South African Health Products Regulatory Authority

SAHPRA · South Africa · africa

Regulatory jurisdiction profileJurisdictional reference
Medical device clearednational regulator

South Africa's SAHPRA (created 2018, replacing the Medicines Control Council) — leech therapy regulated as a medical device under the Medicines and Related Substances Act; traditional-health practitioners under separate THP Council.

Regulatory Profile

Agency type
national regulator
Region
africa
Country
South Africa
Leech status
medical device cleared
Last ASH review
2026-05-25

Relevant Regulation Codes

  • Medicines and Related Substances Act, 1965 (Act 101 of 1965) as amended by Act 14 of 2015 (which created SAHPRA)
  • Traditional Health Practitioners Act, 2007 (Act 22 of 2007)
  • Medical Devices and IVDs Regulations, 2017

Prescriber Requirements

  • HPCSA (Health Professions Council of South Africa)-registered MD
  • SANC (South African Nursing Council)-registered nurse under physician's order
  • Traditional Health Practitioners Council registrants have separate scope, but leech therapy primarily delivered in biomedical clinical settings

Supply Chain & GMP

SAHPRA medical-device licensing per 2017 regulations; English-language IFU.

Import/Export Rules

SAHPRA import licence + Department of Agriculture, Land Reform and Rural Development clearance for live invertebrates. CITES via Department of Forestry, Fisheries and the Environment.

Reimbursement Context

National Health Insurance Act, 2023 implementation pending; private medical schemes (Discovery, Bonitas, GEMS) cover inpatient flap-salvage indications. Outpatient coverage rare.

ASH Editorial Notes

SAHPRA replaced the older MCC in February 2018. South Africa's parallel statutory framework for traditional health practitioners is unusual in Africa; leech therapy in clinical practice remains biomedical-led.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.